Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

LPS-induced NFκB enhanceosome requires TonEBP/NFAT5 without DNA binding.

Lee HH, Sanada S, An SM, Ye BJ, Lee JH, Seo YK, Lee C, Lee-Kwon W, Küper C, Neuhofer W, Choi SY, Kwon HM.

Sci Rep. 2016 Apr 27;6:24921. doi: 10.1038/srep24921.

2.

Nemo-like kinase as a negative regulator of nuclear receptor Nurr1 gene transcription in prostate cancer.

Wang J, Yang ZH, Chen H, Li HH, Chen LY, Zhu Z, Zou Y, Ding CC, Yang J, He ZW.

BMC Cancer. 2016 Mar 31;16:257. doi: 10.1186/s12885-016-2291-4.

3.

The effects of cocaine on HIV transcription.

Tyagi M, Weber J, Bukrinsky M, Simon GL.

J Neurovirol. 2016 Jun;22(3):261-74. doi: 10.1007/s13365-015-0398-z. Epub 2015 Nov 16. Review.

PMID:
26572787
4.

SIRT1 in B[a]P-induced lung tumorigenesis.

Lu J, Zhang M, Huang Z, Sun S, Zhang Y, Zhang L, Peng L, Ma A, Ji P, Dai J, Cui T, Liu H, Gao J.

Oncotarget. 2015 Sep 29;6(29):27113-29. doi: 10.18632/oncotarget.4729.

5.

SUMOylation-disrupting WAS mutation converts WASp from a transcriptional activator to a repressor of NF-κB response genes in T cells.

Sarkar K, Sadhukhan S, Han SS, Vyas YM.

Blood. 2015 Oct 1;126(14):1670-82. doi: 10.1182/blood-2015-05-646182. Epub 2015 Aug 10.

PMID:
26261240
6.

Cocaine promotes both initiation and elongation phase of HIV-1 transcription by activating NF-κB and MSK1 and inducing selective epigenetic modifications at HIV-1 LTR.

Sahu G, Farley K, El-Hage N, Aiamkitsumrit B, Fassnacht R, Kashanchi F, Ochem A, Simon GL, Karn J, Hauser KF, Tyagi M.

Virology. 2015 Sep;483:185-202. doi: 10.1016/j.virol.2015.03.036. Epub 2015 May 15.

PMID:
25980739
7.

Epstein-Barr virus oncoprotein super-enhancers control B cell growth.

Zhou H, Schmidt SC, Jiang S, Willox B, Bernhardt K, Liang J, Johannsen EC, Kharchenko P, Gewurz BE, Kieff E, Zhao B.

Cell Host Microbe. 2015 Feb 11;17(2):205-16. doi: 10.1016/j.chom.2014.12.013. Epub 2015 Jan 29.

8.

Impact of viral activators and epigenetic regulators on HIV-1 LTRs containing naturally occurring single nucleotide polymorphisms.

Shah S, Pirrone V, Alexaki A, Nonnemacher MR, Wigdahl B.

Biomed Res Int. 2015;2015:320642. doi: 10.1155/2015/320642. Epub 2015 Jan 5.

9.

Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ.

Pharmacol Ther. 2015 May;149:150-90. doi: 10.1016/j.pharmthera.2014.12.004. Epub 2014 Dec 27. Review.

10.

HIF-1α restricts NF-κB-dependent gene expression to control innate immunity signals.

Bandarra D, Biddlestone J, Mudie S, Müller HA, Rocha S.

Dis Model Mech. 2015 Feb;8(2):169-81. doi: 10.1242/dmm.017285. Epub 2014 Dec 15.

11.

Leptin attenuates BACE1 expression and amyloid-β genesis via the activation of SIRT1 signaling pathway.

Marwarha G, Raza S, Meiers C, Ghribi O.

Biochim Biophys Acta. 2014 Sep;1842(9):1587-95. doi: 10.1016/j.bbadis.2014.05.015. Epub 2014 May 27.

12.

Interaction of transactive response DNA binding protein 43 with nuclear factor κB in mild cognitive impairment with episodic memory deficits.

Ohta Y, Tremblay C, Schneider JA, Bennett DA, Calon F, Julien JP.

Acta Neuropathol Commun. 2014 Apr 1;2:37. doi: 10.1186/2051-5960-2-37.

13.

Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure.

Mbonye U, Karn J.

Virology. 2014 Apr;454-455:328-39. doi: 10.1016/j.virol.2014.02.008. Epub 2014 Feb 22. Review.

14.

Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR.

Purcell JW, Kim HK, Tanlimco SG, Doan M, Fox M, Lambert P, Chao DT, Sho M, Wilson KE, Starling GC, Culp PA.

Front Immunol. 2014 Jan 8;4:505. doi: 10.3389/fimmu.2013.00505. eCollection 2014.

16.

Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders.

Valor LM, Viosca J, Lopez-Atalaya JP, Barco A.

Curr Pharm Des. 2013;19(28):5051-64. Review.

17.

Cyclin-dependent kinase 2 controls peripheral immune tolerance.

Chunder N, Wang L, Chen C, Hancock WW, Wells AD.

J Immunol. 2012 Dec 15;189(12):5659-66. doi: 10.4049/jimmunol.1202313. Epub 2012 Nov 7.

18.

Acetate reduces microglia inflammatory signaling in vitro.

Soliman ML, Puig KL, Combs CK, Rosenberger TA.

J Neurochem. 2012 Nov;123(4):555-67. doi: 10.1111/j.1471-4159.2012.07955.x. Epub 2012 Sep 28.

19.

Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities.

Porter DC, Farmaki E, Altilia S, Schools GP, West DK, Chen M, Chang BD, Puzyrev AT, Lim CU, Rokow-Kittell R, Friedhoff LT, Papavassiliou AG, Kalurupalle S, Hurteau G, Shi J, Baran PS, Gyorffy B, Wentland MP, Broude EV, Kiaris H, Roninson IB.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13799-804. doi: 10.1073/pnas.1206906109. Epub 2012 Aug 6.

20.

Targeting Huntington's disease through histone deacetylases.

Gray SG.

Clin Epigenetics. 2011 Aug;2(2):257-77. doi: 10.1007/s13148-011-0025-7. Epub 2011 Feb 18.

Items per page

Supplemental Content

Write to the Help Desk